Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: Pharmacological evidence

European Journal of Neuroscience

Volumn 17, Issue 6, 2003, Pages 1306-1312

  Ninan, Ipe ^a,b   Wang, Rex Y ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Clozapine; D1 receptors; Dopamine; NMDA; Prefrontal cortex

Indexed keywords

5 HYDROXYTRYPTOPHAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; LEVODOPA; METIROSINE; N METHYL DEXTRO ASPARTIC ACID; RACLOPRIDE; RESERPINE;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVOKED CORTICAL RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; MALE; MEMBRANE DEPOLARIZATION; NEUROTRANSMISSION; NONHUMAN; PRECURSOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; VOLTAGE CLAMP;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 5-HYDROXYTRYPTOPHAN; ALPHA-METHYLTYROSINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; LEVODOPA; MALE; N-METHYLASPARTATE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RESERPINE; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE;

EID: 0037363708     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2003.02549.x     Document Type: Article

References (44)

1. Arvanov, V.L., Liang, X., Schwartz, J., Grossman, S. & Wang, R.Y. (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther., 283, 226-234.
2. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology, 18, 197-209.
3. 1 receptors within the medial prefrontal cortex. J. Neurosci., 22, 1063-1071.
4. Beasley, C.M. Jr, Tollefson, G.D. & Tran, P.V. (1997) Efficacy of olanzapine: an overview of pivotal clinical trials. J. Clin. Psychiatry, 10, 7-12.
5. Bhana, N., Foster, R.H., Olney, R. & Plosker, G.L. (2001) Olanzapine: an updated review of its use in the management of schizophrenia. Drugs, 61, 111-161.
6. Carlsson, M. & Carlsson, A. (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr. Bull., 16, 425-432.
7. 1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol., 87, 2324-2336.
8. Connors, B.W. & Gutnick, M.J. (1990) Intrinsic firing patterns of diverse neocortical neurons. Trends Pharmacol. Sci., 13, 99-104.
9. Daly, D.A. & Moghaddam, B. (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett., 152, 61-64.
10. Deutsch, S.I., Mastropaolo, J., Schwartz, B.L., Rosse, R.B. & Morihisa, J.M. (1989) A 'glutamatergic hypothesis' of schizophrenia. Rationale for pharmacotherapy with glycine. Clin. Neuropharmacol., 12, 1-13.
11. 1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci., 21, 5546-5558.
12. 1 receptors in prefrontal circuits. Proc. Natl Acad. Sci. USA, 98, 295-300.
13. 5 receptor activation modulates a persistent sodium current in rat prefrontal cortical neurons in vitro. J. Neurophysiol., 84, 75-87.
14. Gulledge, A.T. & Jaffe, D.B. (2001) Dopamine decreases the excitability of layer V pyramidal cells in the rat prefrontal cortex. J. Neurosci., 18, 9139-9151.
15. Hagger, C., Buckley, P., Kenny, J.T., Friedman, L., Ubogy, D. & Meltzer, H.Y. (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry, 34, 702-712.
16. Jardemark, K.E., Ai, J., Ninan, I. & Wang, R.Y. (2001) Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse, 41, 294-300.
17. Jardemark, K.E., Ninan, I., Liang, X. & Wang, R.Y. (2003) Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically-evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience, VV, xxxxxx, in press.
18. Javitt, D.C. (2001) Management of negative symptoms of schizophrenia. Curr. Psychiatry Report, 3, 413-417.
19. Javitt, D.C. & Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 148, 1301-1308.
20. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W. & Holzmuller, B. (1980) Low cerebrospinal fluid gluatamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci. Lett., 20, 379-382.
21. 1A-deficient mutant mice. J. Neurosci., 16, 5870-5882.
22. McCormick, D.A., Connors, B.W., Lighthall, J.W. & Prince, D.A. (1985) Comparative electrophysiology of pyramidal and sparsely spiny neurons of the neocortex. J. Neurophysiol., 54, 782-806.
23. Mohn, A.R, Gainetdinov, R.R., Caron, M.G. & Koller, B.H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell, 98, 427-436.
24. Ninan, I., Jardemark, K.E. & Wang, R.Y. (2003a) Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically-evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse, 48, 66-79.
25. Ninan, I., Jardemark, K.E., Liang, X. & Wang, R.Y. (2003b) Calcium/Calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically-evoked responses in the medial prefrontal cortical pyramidal cells. Synapse, 47, 285-294.
26. 2 receptors in dopamine depleted animals. Psychopharmacology, 142, 175-181.
27. Nomikos, G.G., Iurlo, M., Andersson, J.L., Kimura, K. & Svensson, T.H. (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology, 115, 147-156.
28. Olney, J.W. & Farber, NB. (1995) Glutamate receptor dysfunction and schizophrenia. Arch. General Psychiatry, 52, 998-1007.
29. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science, 251, 947-950.
30. Scott, L., Kruse, M.S., Forssberg, H., Brismar, H., Greengard, P. & Aperia, A. (2002) Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc. Natl Acad. Sci. USA, 99, 1661-1664.
31. 5 receptor modulation o f excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc. Natl Acad. Sci. USA, 98, 301-306.
32. 1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa) /protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci., 18, 10297-10303.
33. Tanaka, E. & North, A.R. (1993) Action of 5-hydroxytryptamine on neurons of rat cingulate cortex. J. Neurophysiol., 89, 1749-1757.
34. Taylor, J.R., Birnbaum, S., Ubriani, R. & Arnsten, A.F. (1999) Activation of cAMP-dependent protein kinase A in prefrontal cortex impairs working memory performance. J. Neurosci., 19, RC23.
35. Tollefson, G.D. & Sanger, T.M. (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry, 154, 466-474.
36. Wang, R.Y., Liang, X., Jardemark, K.E. & Arvanov, V. (2000) Facilitation of NMDA transmission by olanzapine. In: Tran, P.V., Bymaster, F., Tye, N., Herrera, J., Breier, A. & Tollefson, G. (eds), Olanzapine (Zyprexa) - a Novel Antipsychotic. Williams & Wilkins, Baltimore, pp. 114-131.
37. 1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb. Cortex, 11, 452-462.
38. Watanabe, M. & Hagino, Y. (1999) The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum. Eur. J. Pharmacol., 367, 19-23.
39. Weinberger, D.R., Berman, K.F. & Zec, R.F. (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. General Psychiatry, 43, 114-124.
40. Westerink, B.H., de Boer, P., de Vries, J.B., Kruse, C.G. & Long, S.K. (1998) Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur. J. Pharmacol., 361, 27-33.
41. Williams, G.V. & Goldman-Rakic, P.S. (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376, 572-575.
42. Yamamoto, B.K., Pehek, E.A. & Meltzer, H.Y. (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J. Clin. Psychiatry, 55, 8-14.
43. Zheng, P., Zhang, X.X., Bunney, B.S. & Shi, W.X. (1999) Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience, 91, 527-535.
44. Zilles, K. (1985) The Cortex of the Rat. Springer-Verlag, Berlin/Heidelberg.